Recent developments with the establishment of a regulated legal market for new psychoactive substances ('legal highs') in New Zealand

Drug and Alcohol Review

Volumn 33, Issue 6, 2014, Pages 678-680

  Wilkins, Chris ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

COMMERCIAL PHENOMENA; DRUG LEGISLATION; ECONOMICS; HUMAN; LEGISLATION AND JURISPRUDENCE; NEW ZEALAND;

COMMERCE; HUMANS; LEGISLATION, DRUG; NEW ZEALAND; PSYCHOTROPIC DRUGS;

EID: 84926658866     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12203     Document Type: Letter

References (26)

1. New Zealand Parliament. Psychoactive Substances Act 2013. Public Act 2013 No 53. 2013, 17 July. (Archived by WebCite® at http://www.webcitation.org/6MzpzCv3R). Available at: http://www.legislation.govt.nz/act/public/2013/0053/20.0/DLM5042921.html. (accessed January 2014).
2. European Monitoring Centre for Drugs and Drug Addiction. Legal Approaches to Controlling New Psychoactive Substances. 2014. (Archived by WebCite® at http://www.webcitation.org/6Okiup0z3). Available at: http://www.emcdda.europa.eu/topics/pods/controlling-new-psychoactive-substances (accessed April 2014).
3. Munro G, Wilkins C. New Psychoactive Drugs: No Easy Answer. Melbourne, Australia Drug Foundation, 2014. (PolicyTalk).
4. United Nations Office on Drugs and Crime. Global Synthetic Drugs Assessment: Amphetamine-Type Stimulants and New Psychoactive Substances. Vienna, United Nations Office in Drugs and Crime, 2014.
5. Meacher M. Drug policy reform-the opportunity presented by 'legal highs. Psychiatrist 2013;37:249-252.
6. All-Party Parliamentary Group for Drug Policy Reform. Towards a Safer Drug Policy: Challenges and Opportunities Arising from 'Legal Highs'. 2013. (Archived by WebCite® at http://www.webcitation.org/6RSmVaO1O). Available at: http://www.law.qmul.ac.uk/docs/research/90672.pdf (accessed July 2014).
7. Wilkins C. The interim regulated legal market for NPS ('legal high') products in New Zealand: the impact of new retail restrictions and product licensing. Drug Test Anal 2014;6:868-875.
8. New Zealand Parliament. Psychoactive Substances Amendment Act 2014, 2014. (Public Act 2014 No 24; Date of assent 7 May).
9. Ministry of Health. Recall Order Issued under Section 88 of the Psychoactive Substances Act 2013. 2014. (Archived by WebCite® at http://www.webcitation.org/6RSmjB1bA) Available at: http://www.health.govt.nz/system/files/documents/pages/recall-order-v2.pdf (accessed July 2014).
10. Ministry of Health. Regulatory Impact Statement: Amendment to the Psychoactive Substance Act 2013. 2014. (Archived by WebCite® at http://www.webcitation.org/6PwNP33OU). Available at: http://www.health.govt.nz/about-ministry/legislation-and-regulation/regulatory-impact-statements/amendment-psychoactive-substance-act-2013 (accessed May 2014).
11. Schep L. An Update on Calls Received by the National Poisons Centre on Synthetic Cannabinoids (Oct 2010 to May 2014). Dunedin: New Zealand National Poisons Centre; 2014.
12. Wilkins C, Sweetsur P. The impact of the prohibition of BZP legal highs on the prevalence of BZP, new legal highs and other drug use in New Zealand. Drug Alcohol Depend 2013;127:72-80.
13. Sheridan J, Yang Dong C, Butler R, Barnes J. The impact of New Zealand's 2008 prohibition of piperazine-based party pills on young people's substance use: results of a longitudinal, web-based study. Int J Drug Policy 2013;24:412-422.
14. Malczewski A. Psychoactive Substance Use in General Population in 2010: Survey Results. Warsaw, National Bureau for Drug Prevention, 2011.
15. Home Office. Drug Misuse Declared: Findings from the 2011/12 British Crime Survey for England and Wales, 2012. (2nd Edition).
16. Wood D, Greene S, Dargan P. Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emerg Med J 2013;30:70-71.
17. Winstock A, Mitcheson L, Marsden J. Mepedrone: still available and twice the price. Lancet 2010;376:1537.
18. Newcombe R. Mephedrone: the use of mephedrone (M-cat, Meow) in Middlesbrough. Manchester: Lifeline Publications and Research, 2009.
19. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids. Addiction 2013;108:534-544.
20. New Zealand Law Commission. New Psychoactive Substances. Controlling and Regulating Drugs-A Review of the Misuse of Drugs Act 1975. Wellington 2011: 114-48.
21. Birdwell J, Chapman J, Singleton N. Taking drugs seriously: a Demos and UK drug policy commission report on legal highs. London: Demos, 2011.
22. Ministry of Health. Smokefree Law. 2014. (Archived by WebCite® at http://www.webcitation.org/6RSmuE9Y9). Available at: http://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/smokefree-law (accessed July 2014).
23. Noller G. Synthetic Cannabinoid Use in New Zealand: Assessing the Harms. Dunedin, Substance Use and Policy Analysis, 2014. (A report to The STAR Trust).
24. Wood D, Hill S, Thomas S, Dargan P. Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Test Anal 2014;6:850-860.
25. New Zealand Parliament. Psychoactive Substances Amendment Bill-First Reading, Second Reading, In Committee, Third Reading. Hansard (debates); 2014. (6 May). Available at: http://www.parliament.nz/en-nz/pb/debates/debates/50HansD_20140506_00000936/psychoactive-substances-amendment-bill---first-reading (accessed June 2014).
26. Ministry of Health. Code of Manufacturing Practice. 2014. (Archived by WebCite® at http://www.webcitation.org/6RSnDKeab). Available at: http://www.health.govt.nz/our-work/regulation-health-and-disability-system/psychoactive-substances-regulation/code-manufacturing-practice (accessed July 2014).